



Ali Raza Khaki, MD

Clinical Assistant Professor, Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC-2236

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 736-7379

Bio

BIO

Dr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.

In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.

With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.

His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He is the site principal investigator for multiple clinical trials investigating new therapies for genitourinary cancers.

Dr. Khaki is also active working clinically in inpatient oncology and is a Unit Based Medical Director for G1, an oncology hospital unit and is the Director of Inpatient Oncology. In this role, he oversees the inpatient oncology teams, works closely with the cancer center to develop new transitions of care pathways from inpatient to outpatient and has co-led an inpatient oncology research group to study quality improvement, care delivery and end-of-life care for patients with cancer.

Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.

He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.

CLINICAL FOCUS

- Genitourinary Cancer
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Director of Inpatient Oncology, Division of Oncology, (2024- present)
- Unit Based Medical Director, Stanford Healthcare, (2021- present)

HONORS AND AWARDS

- John Quale Travel Fellowship, Bladder Cancer Advocacy Network (BCAN) (2020)
- San Antonio Breast Cancer Symposium Clinical Scholar Award, San Antonio Breast Cancer Symposium (2020)
- Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology (ASCO) (2019 (ASCO Quality Symposium))
- Reza Gandjei Resident Humanism Award, University of California, San Francisco (2016)

PROFESSIONAL EDUCATION

- Residency: UCSF Dept of Internal Medicine (2016) CA
- Board Certification: Hematology, American Board of Internal Medicine (2020)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2020)
- Medical Education: University of California San Diego School of Medicine (2013) CA
- Board Certification, American Board of Internal Medicine , Oncology
- Board Certification, American Board of Internal Medicine , Hematology
- Board Certification, American Board of Internal Medicine , Internal Medicine
- Fellowship, University of Washington, Seattle , Hematology/Oncology
- M.S., University of Washington School of Public Health , Epidemiology (2020)
- Fellowship: Fred Hutchinson Cancer Research Center (2020) WA

Research & Scholarship

CLINICAL TRIALS

- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer, Recruiting
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study, Recruiting
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies, Not Recruiting
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder, Not Recruiting
- HER2 and LA/mUC: A Multi-country Chart Review Cohort Study, Not Recruiting

Publications

PUBLICATIONS

- **Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.**
Zhong, J., Jang, A., Jindal, T., Jiang, C. Y., Thomas, Z., Oh, E., Nguyen, C. B., Bakaloudi, D., Casas, S., Tripathi, A., Grivas, P., Tsung, I., Campbell, et al
LIPPINCOTT WILLIAMS & WILKINS.2026: 696
- **Front-line (1L) treatment and recurrence patterns among patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT).**
Fabrizio, M., Singhal, M., Emond, B., Rossi, C., Bungay, R., Liu, S., Pilon, D., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2026: 708
- **Quality of care (QoC) measures among patients with recurrent, papillary-only bacillus Calmette-Guerin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC).**
Khaki, A., Singhal, M., Emond, B., Rossi, C., Bungay, R., Liu, S., Pilon, D., Fabrizio, M.
LIPPINCOTT WILLIAMS & WILKINS.2026: 709
- **Prognosis of patients (pts) with synchronous vs metachronous metastatic or locally advanced urothelial carcinoma (la/mUC).**
Bakaloudi, D., Makrakis, D., Jindal, T., Miletic, M., Nguyen, C. B., Gupta, S., Ozay, Z., Johnson, J. S., Marmolejo Castaneda, D., Korolewicz, J., Zakopoulou, R., Hui, G., Buznego, et al
LIPPINCOTT WILLIAMS & WILKINS.2026: 695
- **Field-effect-informed urine liquid biopsy for bladder cancer. *Cell***
Shi, W. Y., Liu, K. J., Esfahani, M. S., Mach, K. E., Phillips, N. A., Almanza, D., Bajpai, R. K., Schroers-Martin, J. G., Trabano, L., Lee, T. J., La, V., Rodriguez, G., Holton, et al
2026
- **Treatment Sequencing in Advanced Urothelial Cancer. *Drugs***
Riaz, I. B., Humayun, M. A., Khaki, A. R., Hussain, S. A.
2026
- **Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database. *Clinical genitourinary cancer***
Jang, A., Jindal, T., Khaki, A. R., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Tsung, I., Oh, E., Epstein, I., Bakaloudi, D. R., Jaime-Casas, S., Nizam, A., Glover, et al
2026: 102501
- **Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. *Clinical genitourinary cancer***
Tawagi, K., Khaki, A. R., Chablani, P. V., Hoffman-Censits, J., Koshkin, V. S., Plimack, E. R., Galsky, M. D., Gupta, S., Rosenberg, J. E., Grivas, P., O'Donnell, P. H.
2025: 102487
- **HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG BACILLUS CALMETTE-GUÉRIN (BCG)-EXPERIENCED OR UNRESPONSIVE PATIENTS WITH PAPILLARY-ONLY HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER**
Khaki, A., Singhal, M., Rossi, C., Emond, B., Liu, S., Jiang, P., Bungay, R., Pilon, D., Joshi, K., Fabrizio, M.
ELSEVIER SCIENCE INC.2025
- **Complete response in metastatic renal cell carcinoma: impact of a persistent primary lesion. *BJU international***
Khanna, V., Khaki, A. R.
2025
- **Molecularly Targeted Cancer Medications and Kidney Health. *JAMA network open***
Ziolkowski, S., Long, J., Zhong, Y., Morgan-Cooper, H., Wakelee, H., Khaki, A., Riaz, F., Reddy, S., Leonard, M., Anand, S.
2025; 8 (11): e2541221
- **Genomic Landscape and Outcomes of Renal Cell Carcinoma With Metastases to the Pancreas. *JCO precision oncology***
Glover, M. J., Ashok, A., Khan, O., Kao, C. S., Chiang, R., Hoerner, C. R., Shah, S. A., Srinivas, S., Fan, A. C., Khaki, A. R.

2025; 9: e2500318

- **Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.** *Urologic oncology*
Jindal, T., Jiang, C. Y., Alhalabi, O., Davidsohn, M., Freeman, D., Epstein, I. Y., Bakaloudi, D. R., Talukder, R., Nizam, A., Nguyen, C. B., Oh, E., Tsung, I., Glover, et al
2025
- **Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.** *The oncologist*
Jiang, C. Y., Hwang, H., Epstein, I. Y., Bakaloudi, D. R., Talukder, R., Taylor, A. K., Nizam, A., Jindal, T., Glover, M. J., Khaki, A. R., Barata, P. C., Nguyen, C. B., Oh, et al
2025
- **Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.** *Cancer medicine*
Nizam, A., Nguyen, C. B., Li, J., Zabor, E. C., Msaouel, P., Jiang, C. Y., Alhalabi, O., Oh, E., Davidsohn, M. P., Epstein, I. B., Bakaloudi, D. R., Talukder, R., Jindal, et al
2025; 14 (19): e71284
- **Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.** *European urology*
Jindal, T., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Oh, E., Tsung, I., Bakaloudi, D. R., Talukder, R., Davidsohn, M., Freeman, D., Epstein, I. Y., Ding, C. C., Nizam, et al
2025
- **Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.** *European urology*
Raychaudhuri, R., Khaki, A. R., Redman, M. W., Baker, K. K., Ng, K., Chen, X., Mao, J., Woo, B., Lin, A., Hanochka, A., Conrad, N., Kahugu, M., Panlasigui, et al
2025
- **Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes** *CLINICAL GENITOURINARY CANCER*
Bakaloudi, D., Talukder, R., Enright, T., Leary, J. B., Makrakis, D., Diamantopoulos, L. N., Hobeika, C., Thomas, V., Swami, U., Zakopoulou, R., Bamias, A., Brown, J. R., Pinato, et al
2025; 23 (4): 102356
- **Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.** *JAMA network open*
Joyce, D. D., Wymer, K. M., Graves, J. A., Boorjian, S. A., Gore, J. L., Khaki, A. R., Raldow, A. C., Williams, S. B., Smith, A. B., Sharma, V.
2025; 8 (6): e2517056
- **Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey.**
Khaki, A., Chablani, P. V., Tawagi, K., Grivas, P., Hoffman-Censits, J., Galsky, M. D., Gupta, S., Koshkin, V. S., Plimack, E. R., Rosenberg, J. E., O'Donnell, P. H.
LIPPINCOTT WILLIAMS & WILKINS.2025: e16570
- **Impact of genomic alterations on outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Lu-177 radioligand therapy (RLT)**
Chalker, C., Bergstrom, C. P., Allen, J., Yilmaz, B., Song, H., Khaki, A., Sokolova, A.
LIPPINCOTT WILLIAMS & WILKINS.2025: e17099
- **Baseline hematological parameters and outcomes in patients with prostate cancer treated with Lu-177 PSMA radioligand therapy (RLT): A multicenter real-world analysis**
Bergstrom, C. P., Allen, J., Chalker, C., Song, H., Sokolova, A., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2025: e17047
- **Elevated hernia risk in renal cell carcinoma (RCC) patients treated with tyrosine kinase inhibitors (TKIs): A FAERS analysis.**
Jatwani, K., Kolli, V., Sarangdhar, M., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2025: e16542

- **Unmasking a rare complication: Immune checkpoint inhibitors (ICIs) and Vogt-Koyanagi-Harada (VKH) syndrome.**
Jatwani, K., Kolli, V., Khaki, A., Khosla, A., Sarangdhar, M.
LIPPINCOTT WILLIAMS & WILKINS.2025: e14667
- **Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy.** *JCO oncology practice*
Khaki, A. R., Reynolds, K. L., Petrillo, L. A.
2025: OP2500213
- **Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.** *Clinical genitourinary cancer*
Bakaloudi, D. R., Talukder, R., Enright, T., Leary, J. B., Makrakis, D., Diamantopoulos, L. N., Hobeika, C., Thomas, V. M., Swami, U., Zakopoulou, R., Bamias, A., Brown, J. R., Pinato, et al
2025; 23 (4): 102356
- **PSA response and survival based on metastatic site in patients with metastatic castration resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).**
Allen, J., Bergstrom, C. P., Song, H., Hoffmann, C., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Igaru, A., Khaki, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors.**
Glover, M., Shah, S., Fan, A. C., Srinivas, S., Khaki, A., Johnston, L. J.
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Early findings from a national quality improvement (QI) program to address disparities in bladder cancer (BLCA) care.**
Khaki, A., Sun, F., Hensley, P. J., Dunn, M., Peebles, R., Chisolm, S., Johnson, K., Vira, M. A., Carthon, B., Harvey, A., Mangir, C., Offit, C., Kisiel, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.**
Raychaudhuri, R., Khaki, A., Redman, M., Baker, K. K., Lin, A., Woo, B., Hannoehka, A., Conrad, N., Vakar-Lopez, F., Yezefski, T., Schweizer, M., Montgomery, R., Yu, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC).**
Chablani, P., Khaki, A., Tawagi, K., Grivas, P., Hoffman-Censits, J., Galsky, M. D., Gupta, S., Koshkin, V. S., Plimack, E. R., Rosenberg, J. E., O'Donnell, P. H.
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.** *European urology oncology*
Jindal, T., Jiang, C., Alhalabi, O., Nizam, A., Nguyen, C., Talukder, R., Bakaloudi, D., Davidsohn, M., Freeman, D., Glover, M., Khaki, A. R., Evans, S., Lemke, et al
2024
- **Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.** *Clinical genitourinary cancer*
Talukder, R., Bakaloudi, D. R., Makrakis, D., Diamantopoulos, L. N., Enright, T., Leary, J. B., Raychaudhuri, R., Tripathi, N., Agarwal, N., Jindal, T., Brown, J. R., Zakharia, Y., Rey-Cárdenas, et al
2024; 23 (1): 102284
- **Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.** *Clinical genitourinary cancer*
Bakaloudi, D. R., Talukder, R., Makrakis, D., Diamantopoulos, L., Enright, T., Leary, J. B., Patgunarajah, U., Thomas, V. M., Swami, U., Agarwal, N., Jindal, T., Koshkin, V. S., Brown, et al
2024; 22 (6): 102198
- **An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.** *Journal of medical economics*
Tkacz, J., Ireland, A., Agatep, B., Ellis, L., Balaji, H., Khaki, A. R.

2024: 1-14

- **Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH)**
Rafailia Bakaloudi, D., Makrakis, D., Talukder, R., Nikolaos Diamantopoulos, L., Jindal, T., Nguyen, C. B., Hobeika, C., Thomas, V., Johnson, J., Marmolejo Castaneda, D., Korolewicz, J., Zakopoulou, R., Hui, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023**
Warner, J., Bakow, B. R., Brown, A. J., Choe, J., Fan, E., Ganta, T., Glover, M., Hadfield, M., Hilton, C., Khaki, A., Kothari, S., Lythgoe, M., Nagpal, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort**
Khaki, A., Razak, A., Laurie, S. A., Hwang, C., Diep, A. N., Schmidt, M., Vold, R., Majeed, S., Glatt, D. M., Krystal, J.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.**
Rasco, D. W., Razak, A., Khaki, A., Spira, A. I., Hwang, C., Diep, A. N., Schmidt, M., Vold, R., Majeed, S., Glatt, D. M.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.**
Gage, S., Eteshola, E., Hadfield, M., Hamze, D., Khaki, A., Mishra, S., Rooney, M., Masse, G., Hilal, T., Jain, S., Rubinstein, S., Lythgoe, M., Warner, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.** *European journal of nuclear medicine and molecular imaging*
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, et al
2024
- **Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).**
Bolan, P., Hui, G., Low, Y., Gombar, S., Fan, A. C., Parikh, D., Shah, S., Srinivas, S., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2024: 402
- **Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).**
Khanna, S., Sarwar, N., Caldwell, R., Krell, J., Benjamin, D., Hadfield, M., Khaki, A., Warner, J., Lythgoe, M.
LIPPINCOTT WILLIAMS & WILKINS.2024: 432
- **Describing the genomic landscape of bladder cancer histologic subtypes**
Talukder, R., Berg, R., Huang, M., Nepomucino, V. M., Stoppler, M., Makrakis, D., Yen, A., Mims, M. P., Lerner, S. P., Woldu, S. L., Lotan, Y., Yu, E. Y., Khaki, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 680
- **Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)**
Bakaloudi, D., Talukder, R., Makrakis, D., Diamantopoulos, L., Patgunarajah, U., Thomas, V., Jindal, T., Brown, J. R., Miletic, M., Johnson, J., Hui, G., Buznego, L., Morales-Barrera, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 654
- **Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.**
Jindy, T., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Nizam, A., Basu, A., Bilen, M., Zakharia, Y., Milowsky, M. I., Brown, J. R., Kilari, D., Enamekhoo, H., Hoimes, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 652
- **Comparative cost-effectiveness of trimodal therapy and radical cystectomy for management of muscle-invasive bladder cancer.**
Joyce, D. D., Wymer, K., Boorjian, S. A., Gore, J. L., Khaki, A., Raldow, A., Williams, S. B., Smith, A. B., Sharma, V.
LIPPINCOTT WILLIAMS & WILKINS.2024: 572

- **Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of ¹⁷⁷Lu-PSMA-617 treatment.**
Leonio, M., Ferri, V., Duan, H., Shah, J., Moradi, F., Mari Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, A., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 32
- **Total and anatomically contextualized quantitative ¹⁸F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.**
Song, H., Anand, A., Sjostrand, K., Ferri, V., Duan, H., Shah, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 33
- **Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)**
Bergstrom, C. P., Song, H., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Iagaru, A., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2024: 86
- **The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.** *European urology*
Hensley, P. J., Choudhury, A., Khaki, A. R., Grivas, P., Kamat, A. M.
2023
- **Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study.** *eLife*
Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafla, D. M., Acoba, J. D., Awosika, J., Bakouny, Z., Balmaceda, N. B., Bao, T., Bashir, B., Berg, et al
2023; 12
- **Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.** *Journal of the National Cancer Institute*
El Zarif, T., Nassar, A. H., Pond, G. R., Zhuang, T. Z., Master, V., Nazha, B., Niglio, S., Simon, N., Hahn, A. W., Pettaway, C. A., Tu, S. M., Abdel-Wahab, N., Velev, et al
2023
- **Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma.** *The oncologist*
Bojanini, L., Gupta, N., Khaki, A. R.
2023
- **Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study.** *Targeted oncology*
Storm, E. M., Makrakis, D., Lin, G. I., Talukder, R., Bakaloudi, D. R., Shah, E. E., Liou, I. W., Hockenbery, D., Grivas, P., Khaki, A. R.
2023
- **Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.** *Clinical genitourinary cancer*
Bakaloudi, D. R., Talukder, R., Lin, G. I., Makrakis, D., Diamantopoulos, L. N., Tripathi, N., Agarwal, N., Zakopoulou, R., Bamias, A., Brown, J. R., Pinato, D. J., Korolewicz, J., Jindal, et al
2023
- **Patient-reported distress at a cancer center during the COVID-19 pandemic.** *Scientific reports*
Shah, M. P., Rosenthal, S. W., Roy, M., Khaki, A. R., Hernandez-Boussard, T., Ramchandran, K.
2023; 13 (1): 9581
- **Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes**
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Assessment of price variation in colorectal cancer screening procedures at US hospitals.**
Paranjpe, I., Sharma, P., Wei, C., Puram, V., Kamat, S., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).**

- Talukder, R., Bakaloudi, D., Lin, G., Enright, T., Leary, J., Makrakis, D., Tripathi, N., Agarwal, N., Jindal, T., Koshkin, V. S., Brown, J. R., Johnson, J., Zakharia, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.** *Clinical genitourinary cancer*
Sekar, R. R., Diamantopoulos, L. N., Bakaloudi, D. R., Khaki, A. R., Grivas, P., Winters, B. R., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., Holt, S. K., Gore, J. L., Lin, D. W., Schade, et al
2023
 - **Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.** *medRxiv : the preprint server for health sciences*
Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafia, D. M., Acoba, J. D., Awosika, J., Bakouny, Z., Balmaceda, N. B., Bao, T., Bashir, B., Berg, et al
2023
 - **Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.**
Khaki, A., Fan, A. C., Shah, S., Parikh, D., Chien, J., Moore, K., Ruiz, S., Haas, D., Fakhoury, L., Del Toro, N., Baker, P., O'Brien, A., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database.**
Shen, J., Wang, L., Khaki, A., Jimenez, R. E., Mauer, E., Stoppler, M., Chao, C. Y., Kohli, M.
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**
Jindal, T., Kilari, D., Alhalabi, O., Nizam, A., Khaki, A., Basu, A., Barata, P. C., Bilen, M., Shah, S., Zakharia, Y., Milowsky, M. I., Bellmunt, J., Emamekhoo, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): "Real world" experience.**
Bakaloudi, D., Talukder, R., Makrakis, D., Agarwal, N., Tripathi, N., Bamias, A., Zakopoulou, R., Brown, J., Korolewicz, J., Fulgenzi, C. A. M., Jindal, T., Murgic, J., Frobe, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).**
Talukder, R., Bakaloudi, D., Makrakis, D., Tripathi, N., Agarwal, N., Jindal, T., Koshkin, V. S., Johnson, J., Zakharia, Y., Brown, J., Rey-Cardenas, M., Castellano, D., Alva, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?** *Journal of cancer policy*
Khaki, A. R., Lythgoe, M. P., Prasad, V.
2023; 35: 100402
 - **Geriatric assessment in the older adult with genitourinary cancer: A narrative review.** *Frontiers in oncology*
Singhal, S., Marwell, J. G., Khaki, A. R.
2023; 13: 1124309
 - **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
 - **Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.** *Clinical genitourinary cancer*
Makrakis, D., Bakaloudi, D. R., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Jindal, T., Vather-Wu, N., Zakharia, Y., Tripathi, N., Agarwal, N., Dawsey, S., Gupta, S., Lu, et al
2022

- **Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.** *Cancer investigation*
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., Lythgoe, M. P., Khaki, A. R.
2022; 1-6
- **Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.** *Cancers*
Wagner, M. J., Hennessy, C., Beeghly, A., French, B., Shah, D. P., Croessmann, S., Vilar-Compte, D., Ruiz-Garcia, E., Ingham, M., Schwartz, G. K., Painter, C. A., Chugh, R., Fecher, et al
2022; 14 (17)
- **Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.** *Clinical genitourinary cancer*
Talukder, R., Makrakis, D., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Jindal, T., Koshkin, V. S., Park, J. J., Alva, et al
2022
- **Immune related liver toxicity and potential risk factors: A case-control study**
Storm, E. M., Makraki, D., Lin, G. I., Kennedy, L. C., Shah, E. E., Phipps, A. I., Liou, I. W., Hockenbery, D., Grivas, P., Khaki, A. R.
AMER ASSOC CANCER RESEARCH.2022
- **Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.** *Clinical genitourinary cancer*
Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, et al
2022
- **Use of systemic cancer treatments based on a validated survival prediction model in metastatic cancer.**
Roy, M., Gensheimer, M. F., Chang, D., Singhal, S., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.** *JAMA network open*
Lythgoe, M. P., Desai, A., Gyawali, B., Savage, P., Krell, J., Warner, J. L., Khaki, A. R.
2022; 5 (6): e2216183
- **Using real-world data to assess variations in cost and healthcare utilization for patients diagnosed with bladder cancer.**
Boehmer, L., Khaki, A., Carthon, B., Davis, N. B., Washington, S. L., Goltz, H., Lucas, L., Mangir, C.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18815
- **Patient-reported distress at a cancer center during the COVID-19 pandemic.**
Shah, M. P., Rosenthal, S., Roy, M., Khaki, A., Hernandez-Boussard, T., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18644
- **Reducing inpatient mortality in patients with cancer through multidisciplinary review and targeted interventions.**
Shah, M. P., Garrigues, S. K., Khaki, A., Hansen, J., Divi, V., Blayney, D. W.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study** *EUROPEAN UROLOGY*
Parikh, D. A., Kaki, A., Williams, S. B.
2022; 81 (4): 429-430
- **Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.**
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).**
Makrakis, D., Talukder, R., Dawsey, S., Carril, L., Stewart, T. F., Morales-Barrera, R., Park, J. J., Fulgenzi, C., Murgic, J., Vather-Wu, N., de Kouchkovsky, I., Devitt, M., Di Lorenzo, et al

LIPPINCOTT WILLIAMS & WILKINS.2022

- **Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.**
Golla, V., Shan, Y., Farran, E., Vu, K., Stewart, C. A., Khaki, A., Keegan, K. A., Kamat, A. M., Tyler, D. S., Freedland, S. J., Williams, S. B.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.** *The Lancet. Healthy longevity*
Elkrief, A., Hennessy, C., Kuderer, N. M., Rubinstein, S. M., Wulff-Burchfield, E., Rosovsky, R. P., Vega-Luna, K., Thompson, M. A., Panagiotou, O. A., Desai, A., Rivera, D. R., Khaki, A. R., Tachiki, et al
2022
- **Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.** *European urology*
Parikh, D. A., Khaki, A. R., Williams, S. B.
2022
- **Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.** *Urologic oncology*
Golla, V., Shan, Y., Farran, E. J., Stewart, C. A., Vu, K., Yu, A., Khaki, A. R., Parikh, D. A., Swanson, T. A., Keegan, K. A., Kamat, A. M., Tyler, D. S., Freedland, et al
2022
- **Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature** *JOURNAL OF CANCER METASTASIS AND TREATMENT*
Hui, G., Khaki, A., Grivas, P.
2022; 8
- **Considerations in the reliability and fairness audits of predictive models for advance care planning** *Frontiers in Digital Health*
Lu, J., Sattler, A., Wang, S., Khaki, A. R., Callahan, A., Fleming, S., Fong, R., Ehlert, B., Li, R., Shieh, L., Ramchandran, K., Gensheimer, M., Chobot, et al
2022: 943768
- **Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.** *OncoTargets and therapy*
Chiang, R. S., Glover, M. J., Khaki, A. R., Srinivas, S.
2022; 15: 1259-1269
- **Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.** *Clinical genitourinary cancer*
Talukder, R., Makrakis, D., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., McKay, R. R., Santos, et al
1800
- **Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.** *Cancer*
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., Su, C. T., Khaki, A. R., Osterman, C. K., Glover, M. J., Chiang, R., Makrakis, D., Talukder, et al
2021
- **Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021.** *BJU international*
Glover, M., Hui, G., Chiang, R., Savage, P., Krell, J., Julve, M., Grivas, P., Lythgoe, M., Khaki, A. R.
2021
- **Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.** *JAMA network open*
Schmidt, A. L., Tucker, M. D., Bakouny, Z., Labaki, C., Hsu, C., Shyr, Y., Armstrong, A. J., Beer, T. M., Bijjula, R. R., Bilen, M. A., Connell, C. F., Dawsey, S. J., Faller, et al
2021; 4 (11): e2134330
- **Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room.** *Cancer investigation*
Nath, S. S., Yadav, N. U., Derkach, A., Perez-Johnston, R., Tachiki, L., Maguire, K., Babar, A., Maloy, M. A., Klotz, A., Jee, J., Taur, Y., Chawla, S., Babady, et al
2021: 1-9

- **Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020**
Chiang, R. S., Glover, M., Hui, G., Desai, A., Wakelee, H. A., Lythgoe, M., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer.** *BJU international*
Makrakis, D., Talukder, R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., McKay, R. R., Santos, et al
2021
- **Patients' perception of meaning of life and needed support before and after cancer treatment initiation**
Roy, M., Rosenthal, S., Shah, M., Khaki, A., Hernandez-Boussard, T., Ramchandran, K.
SPRINGER.2021: S156-S157
- **Association of treatment type with patient-reported quality of life in cancer distress screening**
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A., Bozkurt, S., Seto, T., Blayney, D. W., Hernandez-Boussard, T., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.** *JAMA network open*
Sharp, J., Khaki, A. R., Prasad, V.
2021; 4 (9): e2124728
- **Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population.** *JCO oncology practice*
Khaki, A. R., Glisch, C., Petrillo, L. A.
2021: OP2100397
- **Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center.** *Open forum infectious diseases*
Yoke, L. H., Lee, J. M., Krantz, E. M., Morris, J., Marquis, S., Bhattacharyya, P., So, L., Riedo, F. X., Simmons, J., Khaki, A. R., Cheng, G., Greninger, A. L., Pergam, et al
2021; 8 (6): ofab193
- **Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).**
Stewart, T. F., Kotha, N. V., Dzimitrowicz, H., Makrakis, D., Khaki, A., Simon, N. I., Nelson, A., Freeman, D., Rose, T. L., Beck, W., Chawla, N., Pal, S. K., Kilari, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.**
Makrakis, D., Talukder, R., Carril, L., de Kouchkovsky, I., Park, J. J., Bilen, M., McKay, R. R., Agarwal, N., Zakharia, Y., Devitt, M. E., Pinato, D., Hoimes, C. J., Gartrell, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.**
Lythgoe, M., Krell, J., Warner, J., Desai, A., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.**
Wagner, M. J., Ingham, M., Painter, C., Chugh, R., Trent, J. C., Subbiah, V., Khaki, A., Tachiki, L., Loggers, E., Labaki, C., Mckay, R. R., Griffiths, E. A., Thornton, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.**
Loggers, E., Wulff-Burchfield, E., Subbiah, I., Khaki, A., Egan, P., Farmakiotis, D., Phull, H., Nakasone, E., Labaki, C., Yu, P., Joshi, M., Griffiths, E. A., Wise-Draper, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras.** *JCO oncology practice*
Khaki, A. R., Chennupati, S., Fedorenko, C., Li, L., Sun, Q., Grivas, P., Ramsey, S. D., Schwartz, S. M., Shankaran, V.
2021: OP2001050

- **Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.** *Scientific reports*
Michailidou, D., Khaki, A. R., Morelli, M. P., Diamantopoulos, L., Singh, N., Grivas, P.
2021; 11 (1): 9029
- **Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.** *Urologic oncology*
Khaki, A. R., Shan, Y., Nelson, R. E., Kaul, S., Gore, J. L., Grivas, P., Williams, S. B.
2021
- **Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.** *Bladder cancer (Amsterdam, Netherlands)*
Nelson, A. A., Cronk, R. J., Lemke, E. A., Szabo, A., Khaki, A. R., Diamantopoulos, L. N., Grivas, P., Nezami, B. G., MacLennan, G. T., Zhang, T., Hoimes, C. J.
2021; 7 (1): 33-42
- **Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.** *European urology oncology*
Tripathi, A., Khaki, A. R., Grivas, P.
2021
- **Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).**
Makrakis, D., Diamantopoulos, L., Koshkin, V. S., Alva, A., Bilen, M., Stewart, T., Santos, V., Jain, J., Morales-Barrera, R., Devitt, M. E., Carril-Ajuria, L., Nelson, A., Sankin, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.**
Koshkin, V. S., Sun Yilun, Freeman, D., Osterman, C. K., Su, C., Natesan, D., Khaki, A., Makrakis, D., Jain, J., Olsen, A., Basu, A., Barata, P. C., Zakharia, Y., et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.**
Esagian, S. M., Khaki, A., Carril-Ajuria, L., Park, J. J., Bilen, M., Stewart, T., Santos, V., Jain, J., Morales-Barrera, R., Devitt, M., Hoimes, C. J., Shreck, E., Tripathi, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).**
Tucker, M. D., Schmidt, A., Hsu, C., Shyr, Y., Armstrong, A. J., Bakouny, Z., Chapman, C., Dawsey, S., Gartrell, B., Halabi, S., Joshi, M., Khaki, A., Menon, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.**
Lythgoe, M., Julve, M., Krell, J., Savage, P., Grivas, P., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).**
Makrakis, D., Castellano, D., de Kouchkov, I., Park, J. J., Bilen, M., Agarwal, N., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Nelson, A., Gartrell, B. A., Tripathi, A., Bamias, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).**
Khaki, A., Shan, Y., Nelson, R., Kaul, S., Gore, J. L., Grivas, P., Williams, S. B.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.** *Urologic oncology*
Diamantopoulos, L. N., Sekar, R. R., Holt, S. K., Khaki, A. R., Miller, N. J., Gadzinski, A., Nyame, Y. A., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., Gore, J. L., Lin, D. W., Schade, et al
2021

- **Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study**
Khaki, A., Shah, D. P., Lustberg, M. B., Accordino, M. K., Stover, D. G., Nagaraj, G., Rivera, D. R., Perez, E. A., Tolaney, S. M., Peppercorn, J., Grivas, P., Warner, J. L., Painter, et al
AMER ASSOC CANCER RESEARCH.2021
- **Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis.** *Cancer investigation*
Wagner, M. J., Pollack, S. M., Cranmer, L. D., Thompson, M. J., Maxwell, S. n., Wright, S. n., Khaki, A. R., Madeleine, M. M., Grivas, P. n., Kuderer, N. M., Lyman, G. H., Loggers, E. T.
2021: 1–11
- **Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma** *BLADDER CANCER*
Nelson, A. A., Cronk, R. J., Lemke, E. A., Szabo, A., Khaki, A. R., Diamantopoulos, L. N., Grivas, P., Nezami, B., MacLennan, G. T., Zhang, T., Hoimes, C. J.
2021; 7 (1): 33–42
- **Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists.** *Cancer investigation*
Graham, L. S., Sokolova, A. O., Khaki, A. R., Wu, Q. V., Davidson, N. E.
2021; 39 (1): 21–24
- **Loose Regulatory Standards Portend a New Era of Imprecision Oncology.** *Cancer investigation*
Khaki, A. R.
2021: 1–4
- **A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.** *European urology oncology*
Khaki, A. R., Li, A. n., Diamantopoulos, L. N., Miller, N. J., Carril-Ajuria, L. n., Castellano, D. n., De Kouchkovsky, I. n., Koshkin, V. n., Park, J. n., Alva, A. n., Bilen, M. A., Stewart, T. n., Santos, et al
2021
- **Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.** *BJU international*
Esagian, S. M., Khaki, A. R., Diamantopoulos, L. N., Carril-Ajuria, L. n., Castellano, D. n., De Kouchkovsky, I. n., Park, J. J., Alva, A. n., Bilen, M. A., Stewart, T. F., McKay, R. R., Santos, V. S., Agarwal, et al
2021
- **Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.** *Cancer discovery*
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., de Lima Lopes, G., Grivas, P., Painter, C. A., Rini, et al
2020
- **Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.**
Sekar, R., Diamantopoulos, L., Khaki, A., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., Holt, S. K., Gore, J. L., Schade, G. R., Lin, D. W., Hsieh, A., Lee, J., Yezefski, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.**
Diamantopoulos, L., Sekar, R., Khaki, A., Miller, N., Gadzinski, A., Psutka, S. P., Gore, J. L., Schade, G. R., Lin, D. W., Tretiakova, M. S., Vakar-Lopez, F., True, L. D., Hsieh, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.**
Nelson, A., Cronk, R., Szabo, A., Lemke, E., Giever, T. A., Burfeind, J. D., Kilari, D., Riese, M., Bylow, K. A., Diamantopoulos, L., Khaki, A., Wright, M., MacLennan, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.** *Bladder cancer (Amsterdam, Netherlands)*
Diamantopoulos, L. N., Khaki, A. R., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., Lee, J. K., Yezefski, T., Yu, E. Y., Schweizer, M. T., Cheng, H. H., Psutka, S. P., Lin, et al
2020; 6 (1): 71-81

- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al
2020
- **Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes** *BLADDER CANCER*
Diamantopoulos, L. N., Khaki, A., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., Lee, J. K., Yezefski, T., Yu, E. Y., Schweizer, M. T., Cheng, H. H., Psutka, S. P., Lin, et al
2020; 6 (1): 71–81
- **Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer.** *JAMA oncology*
Desai, A. n., Khaki, A. R., Kuderer, N. M.
2020
- **Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.** *Clinical genitourinary cancer*
Diamantopoulos, L. N., Holt, S. K., Khaki, A. R., Sekar, R. R., Gadzinski, A. n., Nyame, Y. A., Vakar-Lopez, F. n., Tretiakova, M. S., Psutka, S. P., Gore, J. L., Lin, D. W., Schade, G. R., Hsieh, et al
2020
- **Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State.** *JCO oncology practice*
Khaki, A. R., Xu, Y. n., Cheung, W. Y., Li, L. n., Fedorenko, C. n., Grivas, P. n., Ramsey, S. n., Shankaran, V. n.
2020; 16 (12): e1543–e1552
- **Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.** *Cancer*
Khaki, A. R., Agarwal, N. n., Pal, S. K., Grivas, P. n.
2020; 126 (20): 4446–50
- **Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board.** *Targeted oncology*
Kennedy, L. C., Wong, K. M., Kamat, N. V., Khaki, A. R., Bhatia, S. n., Thompson, J. A., Grivas, P. n.
2020; 15 (4): 541–48
- **Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature.** *Clinical genitourinary cancer*
Diamantopoulos, L. N., Khaki, A. R., Sonpavde, G. P., Venur, V. A., Yu, E. Y., Wright, J. L., Grivas, P. n.
2020; 18 (3): e266–e276
- **Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.** *The Journal of urology*
Miller, N. J., Khaki, A. R., Diamantopoulos, L. N., Bilen, M. A., Santos, V. n., Agarwal, N. n., Morales-Barrera, R. n., Devitt, M. n., Nelson, A. n., Hoimes, C. J., Shreck, E. n., Assi, H. n., Gartrell, et al
2020; 204 (1): 63–70
- **Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.** *Cancer*
Khaki, A. R., Li, A. n., Diamantopoulos, L. N., Bilen, M. A., Santos, V. n., Esther, J. n., Morales-Barrera, R. n., Devitt, M. n., Nelson, A. n., Hoimes, C. J., Shreck, E. n., Assi, H. n., Gartrell, et al
2020; 126 (6): 1208–16
- **Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis** *LANCET GLOBAL HEALTH*
Di Tanna, G., Khaki, A., Theron, G., McCarthy, K., Cox, H., Mupfumi, L., Trajman, A., Zijenah, L., Mason, P., Durovni, R., Bara, W., Hoelscher, M., Clowes, et al
2019; 7 (2): E191–E199
- **Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Khaki, A. R., Gadi, V. K., Prasad, V. n.
2019; 17 (12): 1456–58

- **Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis** *AMERICAN JOURNAL OF HYPERTENSION*
Rifkin, D. E., Khaki, A. R., Jenny, N. S., McClelland, R. L., Budoff, M., Watson, K., Ix, J. H., Allison, M. A.
2014; 27 (6): 801–10